Feed/Companies/Hangzhou Eli Radiopharma Co., Ltd.

Hangzhou Eli Radiopharma Co., Ltd.

As of 13 Nov 2026, Hangzhou Eli Radiopharma Co., Ltd. has raised $60.0M across 1 verified round on record (amounts in other currencies converted to USD), plus 2 rounds still being checked; latest: nearly RMB 400 million Series A led by Bayland Capital and Huagai Capital, announced 11 Nov 2026.

BUILT ON

Eli Radiopharma specializes in the innovation of radioactive diagnostic and therapeutic drugs for cancer and neurodegenerative diseases.

eliradiopharma.comLinkedInHangzhouBiotechFounded 2024

LATEST ROUND

Series A

$60.0M · 2026-11-11

RAISED ON RECORD · USD

$60.0M

across 1 verified round · plus 2 rounds still being checked

INVESTORS

7 leads

SOURCES

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Rounds

[ 3 ]

Series A

$60.0M · 2026-11-11

led by Bayland Capital, Huagai Capital

Funding round

$14.6M · 2026-03-12

[ HISTORY ]

lead not stated

Pre-seedangel funding round

$13.7M · 2024-12-24

[ HISTORY ]

led by CTS Capital, Huaige Capital, KHK Fund, TaiLong VC, YuanBio Venture Capital

Round	Amount	Announced	Lead	Buzz
Series A	$60.0M nearly RMB 400 million	2026-11-11	Bayland Capital, Huagai Capital	11 outlets. #38 in Trending
12 sources · checked 3 times, last 21h ago [ VERIFIED · CORRECTED ] read against 4 of 12 sources Date 2026-11-11 → 2026-11-12 · eliradiopharma.com The company release dates the announcement Nov. 12, while PRNewswire’s republished version uses Nov. 11; the company release wins. The listed existing shareholders are included because the release says they participated in the round.

Company research

Fetched yesterday

Eli Radiopharma develops radioactive medicines that combine medical imaging and targeted treatment for people with cancer and neurological diseases.

Founders

Feng Yu, Ph.D. · Founder, CEO and Chairman of the Board
Before founding ELI Radiopharma, he served as General Manager and Senior VP of R&D at Suzhou BoomRay, was the domestic person-in-charge at APRINOIA Therapeutics, began his career at GlaxoSmithKline's R&D Center, conducted basic research at the Shanghai Biochemical Cell Institute of the Chinese Academy of Sciences, and holds a master's degree from Fudan University and a Ph.D. from Shanghai University of Traditional Chinese Medicine.

Business model

The company's revenue is generated by providing pharmaceutical R&D and technical consulting services.

WHY IT MATTERS

Eli Radiopharma is trying to combine molecular targeting with radionuclide technology to deliver more precise diagnosis and treatment for oncology and neurological diseases, addressing unmet clinical needs. The company says several programs are approaching IND submission, while its latest nearly RMB 400 million Series A is earmarked for preclinical research, clinical-trial applications, early-stage clinical development, R&D platforms, and hiring.

Checked against 10 sources yesterday

SOURCES

Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$14.6M nearly RMB 100 million	2026-03-12	not stated	No recent discussion
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The source gives a Hangzhou dateline, not the company's headquarters. It also states RMB 300 million in financing to date, which is cumulative rather than this round's financing total. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: eliradiopharma.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent

Pre-seed angel funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$13.7M RMB 100 million	2024-12-24	CTS Capital, Huaige Capital, KHK Fund, TaiLong VC, YuanBio Venture Capital	No recent discussion
2 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 2 sources The source announces an angel funding round led by TaiLong VC and Yuanbio Venture Capital, with four additional participating investors. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: eliradiopharma.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 of 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent

Hangzhou Eli Radiopharma Co., Ltd.

Company

Rounds

Sources

Profile

Investors

Hangzhou Eli Radiopharma Co., Ltd.

Rounds

Company research

Sources

Series A$60.0M2026-11-1112 sources

Funding round$14.6M2026-03-121 source

Pre-seed$13.7M2024-12-242 sources

Investors

Series A$60.0M2026-11-1116 investors

Funding round$14.6M2026-03-124 investors

Pre-seed$13.7M2024-12-2413 investors